Cheshire D R
Department of Medicinal Chemistry, AstraZeneca plc, Bakewell Road, Loughborough, Leicestershire, LE11 5RH, UK.
IDrugs. 2001 Jul;4(7):795-803.
This article reviews the recent literature on selective inhibitors of nitric oxide synthase (NOS) between 1999 and the first quarter of 2001. The introduction highlights the major therapeutic objectives for NOS inhibitors, including rheumatoid arthritis (RA), osteoarthritis (OA) and pain. The review attempts to cover the structural diversity of small molecule NOS inhibitors currently being explored in the pharmaceutical and academic communities.
本文回顾了1999年至2001年第一季度期间关于一氧化氮合酶(NOS)选择性抑制剂的近期文献。引言部分强调了NOS抑制剂的主要治疗目标,包括类风湿性关节炎(RA)、骨关节炎(OA)和疼痛。本综述试图涵盖目前制药界和学术界正在探索的小分子NOS抑制剂的结构多样性。